AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04410445 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03655366 — intervention group
Intervention type: OTHER
Intervention: Questionnaire for Dog owners
Description: Questionnaire directed to epileptic patients, parents of epileptic children and legal representatives of epileptic patients with intellectual disabilities. It includes questions about demographics, epilepsy diagnosis, seizures, the behavior of their dogs around the time they have a seizure and a validates scale to measure dog personality traits.
Study NCT03655366 — intervention group
Intervention type: OTHER
Intervention: Questionnaire for Dog trainers
Description: Questionnaire for seizure response and seizure alert dog trainers including information on number of active working dogs, dog demographic information and selection criteria, the type of patient inclusion criteria they use, training methods used.
Study NCT00088166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCRF
Description: hCRF ; open-label dexamethasone that the patient is currently taking
Study NCT00088166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo hCRF
Description: placebo hCRF 2mg/day and open-label dexamethasone that they are taking
Study NCT01581099 — intervention group
Intervention type: PROCEDURE
Intervention: Digestive Adaptations III surgery
Study NCT00651703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT004-MelQbG10 + Montanide
Study NCT00651703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT004-MelQbG10 + Montanide + Imiquimod
Study NCT03594760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL IV injection
Description: Patient will receive one injection of 18F-DCFPyL and undergo PET-CT imaging
Study NCT04113018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
Description: Experimental
Study NCT03513094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Contraction
Description: Participants were educated on how to contract their transversus abdominis (TA) muscle after having a surface EMG biofeedback device placed on their abdomen to provide audible biofeedback. Participants were asked to ambulate while maintaining TA contraction while ambulating at 50% of maximal volitional isometric contraction.
Study NCT01346293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus
Description: 0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
Study NCT01346293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
Description: 0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
Study NCT01391897 — intervention group
Intervention type: BEHAVIORAL
Intervention: psychotherapy
Description: multimodal complex psychotherapy
Study NCT03062761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula with prebiotics
Description: Intervention group: Partially hydrolysed whey protein based infant formula containing prebiotics.
Study NCT03062761 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Infant Formula
Description: Control group: Intact cow's milk protein based infant formula containing prebiotics
Study NCT02521805 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Animal protein
Study NCT02521805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal protein
Study NCT02521805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetable protein
Study NCT02521805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary fiber (cereal food matrice)
Study NCT02521805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary fiber (meat food matrice)
Study NCT02521805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary fiber (vegetable food matrice)
Study NCT04388553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single shot lumbar Erector Spinae Plane block
Description: unilateral (operative side), performed at L1 level, under ultrasound guidance
Study NCT02100488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin infusion system
Description: Each subject will undergo two Open-loop and two Closed-loop meal tests, each one at 1-2 week intervals, thus completing the 4 experiments in about 6 weeks. The day of the experiment, a standard mixed meal test containing 60 g of carbohydrates (CHO), will be administered. On two occasions, patients will receive in a randomized order the standard insulin bolus based on the individual insulin to CHO ratio (First arm, Open-loop study). On the other two occasions they will receive a Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study). Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
Study NCT03499327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wheat germ oil (UV treated)
Description: Wheat germ oil is naturally rich in vitamin D precursors (ergosterol and 7-dehydrocholesterol), which are converted into vitamin D2 and vitamin D3 by a defined UV light irradiation for the present study (wheat germ oil (UV treated).~The wheat germ oil (UV treated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal.
Study NCT03499327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat germ oil (untreated)
Description: commercial available wheat germ oil The wheat germ oil (untreated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal.
Study NCT04166539 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: You will be asked to complete a questionnaire about your family history of neurological diseases and current and past physical thinking activities.
Study NCT02100488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop insulin infusion system
Description: Standard subcutaneous insulin infusion based on the individual insulin to carbohydrate ratio. Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
Study NCT04166539 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Behavioral and Memory interviews will take place with the patient.
Study NCT04166539 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Have a sample of blood drawn (4.2-5 tablespoons) for clinical and research tests.
Study NCT04166539 — intervention group
Intervention type: RADIATION
Intervention: Magnetic Resonance Imaging
Description: Each MR examination takes about 45 minutes and does not require the use of needles, medication or contrast enhancement. You will lie on your back and enter the MR scanner for the study, during which time you will hear knocking noises. People with pacemakers, aneurysm clips, cochlear implants, or metal/foreign objects in their eyes are not permitted to undergo MR studies. We will review your implants and determine your eligibility.
Study NCT04166539 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Each echocardiogram takes about 30 minutes. This test uses sound waves to look at your heart. The person doing the test will press on your chest with a machine to obtain the pictures. The pressure may be uncomfortable. The echocardiogram will involve an image enhancement agent infusion to obtain better images.
Study NCT01257035 — intervention group
Intervention type: OTHER
Intervention: 18F-FAZA-PET/CT
Description: Contrast fluid injected prior to scan
Study NCT00206934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Either 10 mg of escitalopram or placebo will be administered to a group of healthy volunteers
Study NCT00206934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: escitaolpram
Description: Either 15 mg of escitalopram or placebo will be administered to healthy volunteers
Study NCT05019768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: accelerated custom-fast CXL
Description: The accelerated custom fast CXL (aCFXL) has been developed on a published mathematical model that takes into consideration objective variables such as the equation governing the UVA-induced riboflavin consumption rate and the corneal thickness at its thinnest point. By knowing both values, the mathematical model allows to objectively calculate both the exact UVA irradiation value (intensity), expressed in mW/cm2, and the irradiation time
Study NCT05019768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard CXL
Description: The standard CXL procedure has been carried on following the Dresden protocol
Study NCT02772770 — intervention group
Intervention type: OTHER
Intervention: Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions
Description: The non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions.
Study NCT02772770 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical technique: Transphyseal reconstruction
Description: Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for transphyseal reconstruction with soft tissue graft and metaphyseal fixation.
Study NCT02772770 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical technique: Partial transphyseal reconstruction
Description: Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include partial transphyseal reconstruction (tibial transphyseal and femoral epiphyseal) with soft tissue graft.
Study NCT02772770 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical technique: Physeal sparing reconstruction by the Anderson method
Description: Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for physeal sparing epiphyseal reconstruction with soft tissue graft (Anderson technique).
Study NCT02772770 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method
Description: Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include physeal-sparing with Iliotibial band combined extra-articular and intra-articular reconstructions (Micheli/Kocher Technique).
Study NCT03990506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epi-on PiXL
Description: Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. For masking purposes, epithelial debridement is simulated by moving a scraping instrument in front of the cornea. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen goggles. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; > 50D, 15 J/cm2.
Study NCT03990506 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epi-Off PiXL
Description: Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the corneal epithelium is debrided and the cornea is soaked in Riboflavin by repeated topical application during 10 minutes. The cornea is then illuminated with individually customized topography-guided PiXL under 16:40 minutes. The UV-dosage is individually customized based upon Kmax; \< 45D, 7.2J/cm2; 45-50D, 10J/cm2; > 50D, 15 J/cm2.
Study NCT03243175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5 MG
Description: Apixaban 5mg x 2 during 24 months
Study NCT03243175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: left atrial appendage closure
Description: left atrial appendage closure
Study NCT03141541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group based pain management intervention
Description: The intervention is delivered as six separate sessions of each two hours duration over a four month period. The sessions are managed by a multidisciplinary team from the Spine Center, led by a psychologist. Before the first session, each patient in the intervention group participates in an individual consultation with the psychologist or nurse, with the aim of matching expectations for the group intervention, and hereby ensure the patients compliance throughout the intervention.
Study NCT02102399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal Warm-up
Description: Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
Study NCT02102399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training
Description: Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
Study NCT03652675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention: (Clinician's Guide + HealthCall for HIV/HCV)
Description: This intervention consists of an adaptation of the National Institutes of Health (NIH) Clinician's Guide (CG; NIAAA, 2007) in conjunction with the previously tested HealthCall smartphone app program (Hasin et al., 2013; Hasin et al., 2014). Participants will complete a brief baseline meeting (\~20 minutes) with a counselor to discuss alcohol use, liver function, and HIV medication adherence. They will track their drinking using HealthCall for 60 days, with brief follow-up meetings with their counselor to check in about their drinking 30 and 60 days later.
Study NCT00745797 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
Study NCT01524081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole, Cefuroxime
Description: administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.~1. - Cefuroxime in 100ml saline~2. - Metronidazole in 500ml saline
Study NCT01524081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin (+ clavulanic acid) and Fluconazole
Description: Administration of amoxicillin (+ clavulanic acid) 2.4 g and Fluconazole 800mg in 2 following intravenous infusions 60 minutes prior the surgery.~1. - 2x amoxicillin in 100ml saline~2. - Fluconazole in 500ml saline
Study NCT01524081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 100ml saline solution~2. - 500ml saline solution
Study NCT01524081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~1. - 2x 100ml saline solution~2. - 500ml saline solution
Study NCT04115982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: One vial every 15 days during 2 months
Study NCT04115982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: One vial every 15 days during 2 months
Study NCT03753399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combining with electro-acupuncture at fixted acupoints.
Study NCT00474461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treatment group
Description: Intracoronary injection of cardiac stem cells
Study NCT01085032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine
Description: Subjects in the experimental group receive six weeks of nicotine patch treatment, 24 hour dose, using a step-down algorithm. Participants who smoke greater than 10 cigarettes/day receive two weeks of 21 mg patch, followed by two weeks of 14 mg patch, and then two weeks of 7 mg patch. Participants who smoke 5-9 cigarettes per day receive four weeks of 14 mg patch, followed by two weeks of 7 mg.
Study NCT01085032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nicotine patch
Description: Subjects in the placebo condition receive an inert placebo patch matched for size, shape, color, and packaging.~The same step-down dosing algorithm as in the experimental condition is used.
Study NCT01084681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular treatment of intracranial aneurysms
Description: Endovascular treatment with the SILK Artery Reconstruction Device for occluding intracranial aneurysms.
Study NCT01084681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular treatment of intracranial aneurysm with coils
Description: Endovascular treatment with commercially available intracranial coils for occluding intracranial aneurysms.
Study NCT04832763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample
Study NCT04832763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Review of medical charts
Study NCT04832763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Undergo physical function testing
Study NCT04832763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04832763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT02441556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endovascular treatment
Description: The endovascular treatment is comprised of thrombolysis, mechanical thrombectomy, stenting, or a combination of all these approaches. Generally, Solitaire FR is preferred, other devices such as Trevo or future advanced devices can also be considered which will be decided by the executive committee.
Study NCT02441556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard medical therapy
Description: If the patient meets the criteria for IV rt-PA within 4.5 h of stroke onset, he/she will receive a single alteplase dose of 0.9 mg/kg IV(maximum dose: 90mg), with 10% given as a bolus, followed by continuous IV infusion of the other dose within 1h. All patients will receive standard medical therapy. The standard medical therapy conforms with the current American Heart Association/American Stroke Association guidelines.
Study NCT02441556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard medical therapy
Description: If the patient meets the criteria for IV rt-PA within 4.5 h of stroke onset, he/she will receive a single alteplase dose of 0.9 mg/kg IV(maximum dose: 90mg), with 10% given as a bolus, followed by continuous IV infusion of the other dose within 1h. All patients will receive standard medical therapy. The standard medical therapy conforms with the current American Heart Association/American Stroke Association guidelines.
Study NCT04594824 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: no intervention
Study NCT00651703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT004-MelQbG10 + Imiquimod
Study NCT00651703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT004-MelQbG10 intra nodal injection